Dr. Kundan Singh Chufal

Professional Journey

Achievements

• Pioneering Advanced Radiotherapy: Instrumental in developing North India’s first IMRT program and integrating image-guided and gating techniques into routine clinical practice early in his career. This innovation significantly improved treatment accuracy for patients in the region.
• Best Radiation Oncologist of the Year (2017): Honored with this award in recognition of excellence in patient care and leadership in the field.
• ASSOCHAM Medical Travel Award (2017): Received the ASSOCHAM award for Best Oncology Department (Medical Value Travel) in 2017, presented by the Minister of External Affairs, for contributing to a department that excelled in treating international patients.
• Best Publication Award (2023): Awarded for authoring an outstanding research paper on esophageal cancer treatment – a study that represented the most extensive Indian experience with neoadjuvant therapy followed by surgery, reflecting the impact of his team’s work on improving cancer care standards.
• Dr. Chufal has been an invited speaker at various oncology forums and has served on editorial boards of oncology journals, underscoring his standing in the professional community

Research and Publications

• Dr. Kundan Singh Chufal has an impressive academic portfolio with over 120 publications in peer-reviewed medical journals. His team’s recent research demonstrates consistent innovation, clinical excellence, and commitment to enhancing patient care through advanced, evidence-based practices. Here are some highlights:

• Advancing Esophageal Cancer Treatment

  In 2023, Dr. Chufal and colleagues published a landmark 10-year study involving 254 patients with locally advanced esophageal cancer treated with a tri-modality approach—neoadjuvant chemoradiotherapy followed by surgery. This significant Indian study demonstrated excellent outcomes, including high rates of pathological complete response and prolonged survival, earning recognition as the “Best Published Paper” of 2023. Read More

• Insights into Rare Cancers (Thymoma)Dr. Chufal’s team conducted India’s largest study on thymoma, reviewing over 80 cases. Published in 2023, this research highlighted improved survival outcomes through aggressive multimodal treatment (surgery, radiotherapy, chemotherapy), reinforcing the importance of specialized, team-driven care for rare cancers. Read More
  

  Innovation in Technology and Artificial Intelligence

  A pioneer in integrating technology with oncology care, Dr. Chufal authored a comprehensive review (2023) on Artificial Intelligence in Radiation Oncology. His work elucidates how AI significantly enhances radiotherapy processes—from automated treatment planning to predictive analytics—enabling precise tumor targeting and optimized patient care. Read More

  Patient Safety and Quality of Care

  In a 2024 study focusing on cardiac safety during radiotherapy for breast cancer, Dr. Chufal’s team meticulously assessed cardiac biomarkers (troponin, BNP) in patients undergoing left-sided radiotherapy. Their findings confirmed no significant cardiac impact when employing advanced heart-sparing techniques, underscoring his commitment to safe and effective cancer treatments. Read More

• Machine Learning to Improve Radiotherapy Patient SelectionIn a recent groundbreaking publication (2025), Dr. Chufal developed a machine learning model to predict eligibility for Deep Inspiration Breath Hold (DIBH) radiotherapy in patients with left-sided breast cancer. This innovative model, leveraging data from initial assessments, significantly streamlined patient selection, reduced unnecessary assessments by 20%, and optimized resource allocation in busy clinical settings. This pioneering work emphasizes his team’s commitment to improving patient experience and outcomes through technology-driven solutions. Read MoreDr. Chufal’s continuous contributions to clinical research and technological advancement ensure his patients consistently receive world-class, cutting-edge cancer care.Overall, Dr. Chufal’s prolific research contributions – spanning common cancers such as lung, breast, sarcoma, head and neck, and cervix, as well as rare entities – ensure that the most up-to-date evidence continually informs his clinical practice. He frequently presents his work at national and international conferences and collaborates with multidisciplinary teams on clinical trials. For patients choosing Dr. Chufal as their physician, this means they are under the care of a physician who not only uses established best practices but also actively defines them through research. His dedication to advancing the science of cancer therapy ultimately translates into more effective, innovative, and personalized treatment options at the bedside.